Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 20/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5050922 | 0.76 | CXCR4 (0.50) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL4828641 | 0.74 | CXCR4 (0.48) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL3312985 | 0.74 | CXCR4 (0.48) | CXCR4CYP2D6 | |
| SCHEMBL4074278 | 0.73 | CXCR4 (0.52) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL3313097 | 0.72 | HDAC6 (0.42) | CXCR4 | |
| SCHEMBL3375140 | 0.71 | CXCR4 (0.47) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL3314059 | 0.71 | CXCR4 (0.56) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL3314915 | 0.70 | HDAC6 (0.42) | CXCR4 | |
| Trifluoroacetic Acid SCHEMBL4541649 | 0.70 | CXCR4 (0.49) | CXCR4CYP2D6KCNH2 | |
| SCHEMBL7846052 | 0.69 | CXCR4 (0.56) | CXCR4CHRM2CYP2D6DRD2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317445-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2009-03-11 | — | — | EP | disclosed |
| US-7396840-B2 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION (US) | 2008-07-08 | — | — | US | disclosed |
| US-7084155-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2006-08-01 | — | — | US | disclosed |
| US-20060128750-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2006-06-15 | — | — | US | disclosed |
| US-6864265-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED, INC. (CA) | 2005-03-08 | — | — | US | disclosed |
| US-20040220207-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-11-04 | — | — | US | disclosed |
| EP-1317445-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | disclosed |
| US-20030018046-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2003-01-23 | — | — | US | disclosed |
| WO-2002022600-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220207-A1 | Chemokine receptor binding heterocyclic compounds | CXCR3, ACKR3, CCR2 | CXCR4 7/4885CHRM2 1559/4885CYP2D6 3122/4885 |
| US-20060128750-A1 | Chemokine receptor binding heterocyclic compounds | CXCR4, CCR5, CXCR3 | CXCR4 1/4885CHRM2 1017/4885CYP2D6 3062/4885 |
| US-20030018046-A1 | Chemokine receptor binding heterocyclic compounds | CXCR3, ACKR3, CCR2 | CXCR4 7/4885CHRM2 1559/4885CYP2D6 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.